ND Biosciences was founded to develop and preclinically validate next-generation therapeutics and diagnostics for neurodegenerative diseases.

The therapies developed at ND Biosciences focus on treating both early and late stages of neurodegenerative diseases (NDs). This is accomplished by developing combination therapies that can prevent the initiation of protein aggregation in the first place, and that neutralize the activities of existing aggregates.

ND Biosciences has developed integrated proprietary platforms that enable transformative drug discovery and preclinical development programs. These platforms are based on unique capabilities and model systems that allow ND Biosciences to:

  1. Reverse-engineer the complexity of ND protein pathologies under controlled conditions
  2. Reproduce key processes underlying pathology formation and neurodegeneration in living neurons
  3. Develop novel companion diagnostic assays and imaging agents that capture the diversity and complexity of protein pathology in the brain.



ND Biosciences is a 2019 spinoff from the Lashuel Lab at the École Polytechnique Fédérale de Lausanne (EPFL), and is hosted since 2020 at StartLab, as part of Biopole’s competitive startup incubation program.